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INTRODUCTION
Clostridium difficile is a major cause of nosocomial
antibiotic-associated diarrhea [1]. Toxins A (enterotoxin;
TcdA) and B (cytotoxin; TcdB) are well-known primary
virulence factors of C. difficile [2]. These toxins are encod-
ed by 2 separate genes, tcdA and tcdB, which are located
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Background: Clostridium difficile is a major cause of antibiotic-associated diarrhea. The objective
of this study was to characterize clinical isolates of C. difficile obtained from various regions in Korea
with regard to their toxin status, molecular type, and antimicrobial susceptibility. 
Methods: We analyzed a total of 408 C. difficile isolates obtained between 2006 and 2008 from
408 patients with diarrhea in 12 South Korean teaching hospitals. C. difficile toxin genes tcdA, tcdB,
cdtA, and cdtB were detected by PCR. Molecular genotyping was performed by PCR ribotyping.
Antimicrobial susceptibilities of the 120 C. difficile isolates were assessed by agar dilution methods.
Results: Among 337 toxigenic isolates, 105 were toxin A-negative and toxin B-positive (A-B+) and
29 were binary toxin-producing strains. PCR ribotyping showed 50 different ribotype patterns. The
5 most frequently occurring ribotypes comprised 62.0% of all identified ribotypes. No isolate was
susceptible to cefoxitin, and all except 1 were susceptible to piperacillin and piperacillin-tazobac-
tam. The resistance rates of isolates to imipenem, cefotetan, moxifloxacin, ampicillin, and clindamycin
were 25%, 34%, 42%, 51%, and 60%, respectively. The isolates showed no resistance to metron-
idazole or vancomycin. 
Conclusions: This is the first nationwide study on the toxin status, including PCR ribotyping and
antimicrobial resistance, of C. difficile isolates in Korea. The prevalence of A-B+ strains was 25.7%,
much higher than that reported from other countries. Binary toxin-producing strains accounted for
7.1% of all strains, which was not rare in Korea. The most prevalent ribotype was ribotype 017, and
all A-B+ strains showed this pattern. We did not isolate strains with decreased susceptibility to metron-
idazole or vancomycin. (Korean J Lab Med 2010;30:491-7)
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in the pathogenicity locus of the chromosome called PaLoc
[3, 4]. 
Toxigenic isolates of C. difficile usually produce both
toxins A and B. Toxin A-negative and toxin B-positive
(A-B+) strains of C. difficilewere first described in the early
1990s [5,6]. A-B+ strains fail to produce detectable amounts
of toxin A due to a deletion in the repeating sequence of
the tcdA gene. However, A-B+ strains have been associ-
ated with clinical conditions ranging from asymptomatic
carriage to fatal pseudomembranous colitis. Alfa et al.
[7] reported convincing evidence that indicates that these
strains have been responsible for outbreaks in hospitals. 
Some isolates of C. difficile produce an additional binary
toxin (actin-specific ADP-ribosyltransferase toxin, CDT),
whose role in C. difficile-associated disease (CDAD) is
unclear [8]. The 2 genes cdtA and cdtB encode the enzy-
matic (CDTa) and binding (CDTb) components of the
binary toxin. These genes are located on the CDT locus
of the chromosome but are not part of the PaLoc [8, 9].
The prevalence of A-B+, and binary toxin-producing C.
difficile strains varies geographically [10].
Recently, outbreaks of CDAD due to an emerging strain
of C. difficile (PCR ribotype 027) associated with high mor-
bidity and mortality have been reported in Canada, the
United States, and Europe [11]. This strain produces a
binary toxin and has deletions in tcdC, a putative nega-
tive regulator for toxins A and B [11, 12]. The epidemic
strain is resistant to gatifloxacin and moxifloxacin, and
increasing use of fluoroquinolone has been considered a
risk factor in these outbreaks [11]. The most commonly
used drugs for the treatment of CDAD are metronidazole
(MTZ) and vancomycin (VAN). C. difficile is considered to
be susceptible to both agents, and therefore, the in vitro
activity of these agents against C. difficile isolates is rarely
performed in most centers. However, a few reports have
been published regarding elevated minimum inhibitory
concentrations (MIC) of MTZ and VAN against C. difficile
[13]. Moreover, increased resistance to antimicrobial agents
has played a role in their selection in hospital environ-
ments [14].
The objective of this study was to characterize clinical
isolates of C. difficile associated with diarrhea through-
out South Korea with regard to their toxin status, molec-
ular typing, and antimicrobial susceptibility. 
MATERALS AND METHODS
1. Bacterial strains 
We obtained and analyzed 408 unduplicated isolates of
C. difficile recovered between 2006 and 2008 from 408
patients with diarrhea in 12 tertiary teaching hospitals
in 7 regions of Korea. We received C. difficile isolates or
frozen stool samples from all 12 hospitals. Stool samples
were cultured anerobically on C. difficile selective agar
(CDSA, Becton Dickinson and Company, Sparks, MD, USA)
for 48 hr at 37℃. Species identification was performed
on the basis of typical morphology on agar plates as well
as characteristic odor and ATB 32A system results
(BioMerieux SA, Marcy I’Etoile, France). The reference
strains VPI 10463, 3608/03, SE844, 48489, 1470, and
UK078 were supplied by Dr. Maja Rupnik, Michel Delmee,
and Thomas V. Riley. 
2. Toxin analysis by PCR
C. difficile toxin genes were detected by PCR as
described previously [15, 16]. The primer pairs used were
NK9-NK11 for the repetitive domain of tcdA, NK104-
NK105 for tcdB, cdtA pos-cdtA rev for cdtA, and cdtB
pos-cdtB rev for cdtB.
3. PCR ribotyping
PCR ribotyping was performed as previously described
with the primers 5′-CTGGGGTGAAGTCGTAACAAGG-
3′(position 1445 to 1466 of the 16S rRNA gene) and 5′-
GCGCCCTTTGTAGCTTGACC-3′(position 20 to 1 of the
23S rRNA gene) [17]. Comparison of the PCR ribotyping
patterns was performed visually. Ribotype patterns that
differed by at least 1 band were assigned to different
types. Ribotype groups were designated by upper- and
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lower-case letters combined with a number.
4. tcdC sequencing
The tcdC gene was PCR-amplified with the primers
PaL15 and PaL16 on the ribotype 027 strain as previous-
ly described [18]. Amplicons were sequenced commer-
cially (Macrogen, Seoul, Korea). The analyzed amino
acid sequences were compared to the published tcdC
sequence for strain VPI10463 [18]. 
5. Antimicrobial susceptibility testing 
Antimicrobial susceptibility tests were performed with
120 C. difficile isolates using 10 randomly selected iso-
lates per hospital and the agar dilution method on Bru-
cella blood agar according to the recommendations of the
CLSI [19]. Quality control strains used for susceptibility
testing included Bacteroides thetaiotaomicron (ATCC
29741) and B. fragilis (ATCC 25285). Antimicrobial agents
used were ampicillin (Sigma-Aldrich Co., St. Louis, MO,
USA), piperacillin and tazobactam (Yuhan, Seoul, Korea),
cefoxitin (Merck Sharp & Dohme, West Point, PA, USA),
cefotetan (Daiichi Pharmaceutical, Tokyo, Japan), clin-
damycin (Korea Upjohn, Seoul, Korea), imipenem and
metronidazole (Choong Wae, Seoul, Korea), moxifloxacin
(Bayer Korea, Seoul, Korea), and vancomycin (Chong Kun
Dang, Seoul, Korea). For the combination of piperacillin
and tazobactam, a constant amount of tazobactam (final
concentration, 4 mg/mL) was added to piperacillin. The
CLSI breakpoints were used for the analysis. However,
the CLSI guidelines do not recommend a breakpoint for
VAN, and therefore the breakpoint suggested by the
European Committee on Antimicrobial Susceptibility
Testing (EUCAST; www.escmid.org/research_projects/
eucast) was used. 
RESULTS
1. Toxin analysis by PCR 
Of the total 408 isolates, 337 (82.6%) were toxigenic C.
difficile (A+B+ and A-B+). We identified 232 (56.9%) A+B+
strains and 105 (25.7%) A-B+ strains. The recovery rates
of the toxigenic strains were 70-100% according to the
hospitals studied. The proportion of A-B+ strains differed
between the hospitals during the study period (from 0%
to 37.9%). 
Twenty-nine (7.1%) strains were CDT+. The proportion
of CDT+ strains varied between the hospitals (from 0% to
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*data from the Korean Hospital Association 2007.
Abbreviations: A+B+, toxin A-positive, toxin B-positive; A-B+, toxin A-negative, toxin B-positive; A-B-, toxin A-negative, toxin B-negative, CDT+, binary
toxin-positive; CDT-, binary toxin-negative.
Hospitals N of isolates tested Study period Number of beds*
N (%)
A+B+CDT- A+B+CDT+ A-B+CDT- A-B-CDT-
Seoul A 145 Jan.2007-Dec. 2007 2,064 52 (35.9) 8 (5.5) 55 (37.9) 30 (20.7)
Seoul B 37 Jan.2007-Jun.2008 758 19 (51.4) 4 (10.8) 9 (24.3) 5 (13.5)
Seoul C 30 Jan.2007-Feb.2008 938 13 (43.3) 6 (20.0) 6 (20.0) 5 (16.7)
Seoul D 20 Jan.2008-Feb.2008 2,200 8 (40.0) 3 (15.0) 3 (15.0) 6 (30.0)
Gyeonggi A 41 Jun.2007-Mar.2008 589 23 (56.1) 2 (4.9) 9 (21.9) 7 (17.1)
Gyeonggi B 17 Jan. 2008-May. 2008 920 14 (82.3) 1 (5.9) 2 (11.8) 0 (0)
Gyeonggi C 15 Jan.2006-Dec. 2006 550 8 (53.3) 0 (0) 3 (20.0) 4 (26.7)
Chungnam 22 Oct.2007-May.2008 803 12 (54.5) 2 (9.1) 6 (27.3) 2 (9.1)
Daejeon 25 Mar.2008-Jun.2008 813 17 (68.0) 2 (8.0) 3 (12.0) 3 (12.0)
Busan 20 Feb.2007-Dec. 2007 912 12 (60.0) 0 (0) 6 (30.0) 2 (10.0)
Gwangju 20 Mar.2008-Jun.-2008 555 15 (75.0) 0 (0) 0 (0) 5 (25.0)
Gangwon 16 Nov.2007-May.2008 816 10 (62.5) 1 (6.3) 3 (18.8) 2 (12.5)
Total 408 203 (56.9) 29 (7.1) 105 (25.7) 71 (17.4)
Table 1. The frequencies of the occurrences of toxins A-, B-, and binary toxin-producing strains in 12 South Korean hospitals
20.0%). All CDT+ strains were A+B+ (Table 1). 
2. PCR ribotyping 
A total of 50 different ribotype patterns were found.
We identified 24 patterns of A+B+ CDT- strains (ribotype
AB1-AB24), 12 A+B+ CDT+ (ribotype C1-C12), and 13 A-B-
(ribotype ab1-ab13). The PCR ribotypes aB, C5, and C2
are equivalent to the PCR ribotypes 017, 027, and 078 by
O’Neill’s method, respectively [17] (Fig. 1).
All A-B+ strains showed the same banding pattern (ribo-
type aB) in ribotyping, which was identical to the pat-
tern of the C. difficile 1470 strain (ribotype 017). Ribo-
type aB was the predominant type (105 isolates, 25.7%).
The most frequently observed ribotypes of C. difficile in
decreasing order were as follows: ribotype AB2 (71, 17.4%),
ribotype AB3 (30, 7.4%), ribotype AB1 (27, 6.6%), and ribo-
type AB17 (20, 4.9%). These 5 ribotypes comprised 62.0%
of the total. Ribotypes of C. difficile isolates were differ-
ent from their toxin statuses. 
Only 1 C. difficile isolate showed a pattern (ribotype C5)
identical to PCR ribotype 027. Sequence analysis of tcdC
in this isolate showed a single-base pair deletion at posi-
tion 117 as well as a well-documented 18-bp deletion, which
was identical to the sequence results of the epidemic strain
of C. difficile 027. When examined by the E-test, the
isolate was susceptible to moxifloxacin (MIC=0.5 mg/mL). 
Thirteen strains of PCR ribotype 078 (ribotype C2) were
identified in 6 hospitals, making ribotype 078 the most
prevalent ribotype among CDT+ strains (13/29 CDT+ strains,
44.8%; 13/408 isolates, 3.1%).
3. Antimicrobial susceptibility testing 
The in vitro activities of antimicrobial agents against
C. difficile isolates are summarized in Table 2. No iso-
lates were susceptible to cefoxitin and all except 1 were
susceptible to piperacillin and piperacillin-tazobactam.
The resistance rates to imipenem, cefotetan, moxifloxacin,
ampicillin, and clindamycin were 25%, 34%, 42%, 51%,
and 60%, respectively. All strains were susceptible to
metronidazole and vancomycin. 
DISCUSSION
We conducted this study to enhance the knowledge on
the nationwide epidemiology of C. difficile. This study
included data from 12 hospitals in 7 different areas of
South Korea.
The prevalence of A-B+ strains differs according to the
country studied. In Europe, 6.2% of toxigenic C. difficile
isolates recovered in 2005 were A-B+ [10]. In a recent
study, A-B+ strains comprised 33.3% of 75 toxigenic iso-
lates from Shanghai and 0% of 80 isolates from Stock-
holm [20]. The prevalence of A-B+ strains was 25.7% (0-
37.9%, according to the data obtained from hospitals) in
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Fig. 1. PCR ribotype patterns of the Clostridium difficile isolates
representing PCR ribotypes AB24, C11, C5, C2, AB14, AB23,
and aB (Lane 1 to 7, respectively). Lane L refers to 100 bp lad-
der. Banding patterns of the C5, C2, and aB ribotypes were iden-
tical to the pattern of C. difficile ribotype 027, 078, and 017 strains. 
L 1 2 3 4 5 6 7 L
500 bP
300 bP
Abbreviations: MIC, minimum inhibitory concentration; S, Susceptible;
I, Intermediate; R, Resistant.
Antimicrobials
MIC (mg/mL)
S I R
Range MIC50 MIC90
Ampicillin 1-8 2 2 0 49 51
Piperacillin 2-64 8 16 99 1 0
Piperacillin- 4-64 8 16 99 1 0
tazobactam
Cefoxitin 64->128 128 >128 0 0 100
Cefotetan 8->128 32 128 26 40 34
Clindamycin 0.5->128 128 >128 11 29 60
Imipenem 2-64 8 16 22 53 25
Metronidazole 0.12-8 1 4 100 0 0
Moxifloxacin 1->128 2 16 53 5 42
Vancomycin 0.25-2 0.5 1 100 0 0
Table 2. The MICs of 10 antimicrobial agents for 120 Korean
Clostridium difficile isolates
this study. In our previous study, the prevalence of A-B+
strains increased steadily (4.2% in 1995, 39.6% in 2004)
[21], and in another multicenter study conducted in Korea,
17.6-54.8% of the isolated strains were A-B+ in 2005 [22].
The prevalence of A-B+ strains in Korea and Shanghai
was much higher than in European countries. 
The prevalence of CDT+ strains was 7.1% (0-20.0%) in
this study. Before the epidemics caused by ribotype 027,
a binary toxin was identified in about 6% of clinical C.
difficile isolates obtained in the United States and Europe
[16, 23]. The prevalence of CDT+ C. difficilestrains increased
to 34.6% due to the ribotype 027 epidemics in Canada [24].
In our previous study, the prevalence of CDT+ strains
increased from 0% in 2003 to 3.9% in 2006 [21]. There-
fore, we thought the prevalence of CDT+ strains had
steadily increased without evidence of a C. difficile epi-
demic. All CDT+ strains were A+B+. Therefore, no addi-
tional binary toxin test was required for the diagnosis of
CDAD. 
A total of 408 C. difficile isolates were successfully typed
with our PCR ribotyping method. Predominant ribotypes
among the participating hospitals were not significantly
different.   
All 105 A-B+ strains showed the same ribotyping pattern
(aB), which was the most common ribotype (105/408, 25.7%)
and indistinguishable from the pattern of C. difficile 1470
(ribotype 017). It was previously reported that most A-B+
strains yield this distinct ribotype pattern in many stud-
ies, suggesting a worldwide clonal spread [7, 10, 21]. 
Only 1 PCR ribotype 027 strain was identified in hos-
pital Seoul A. In contrast to epidemic 027 strains resis-
tant to fluoroquinolone, this isolate was susceptible, which
is in accordance with a report on 027 isolates obtained
before 2001 in North America [11].
PCR ribotype 078 is the predominant ribotype in calves
and pigs, and is an emerging new hypervirulent strain
[25]. The prevalence of CDAD caused by a PCR ribotype
078 strain increased from 3% to 13% during 2005-2008
in The Netherlands. CDAD caused by type 078 strains
has a similar severity of CDAD caused by type 027 strains
[26]. Thirteen strains of PCR ribotype 078 were identi-
fied in our study, which was the most prevalent ribotype
among CDT+ strains (44.8% of CDT+ strains, 3.1% of all
isolates).
Antimicrobial therapy plays a central role in the devel-
opment of CDAD. The increasing use of fluoroquinolones
in US health care facilities may have provided a selec-
tive advantage for the fluoroquinolone-resistant 027
strain and promoted its widespread emergence [11]. MTZ
and VAN remain the most active agents in this study.
No resistance to piperacillin-tazobactam was found in
isolates from Shanghai and Stockholm [20] and only 1
non-toxigenic isolate showed intermediate resistance in
this study. Resistance to other antimicrobials varies widely
between countries [29]. The resistance rate to moxifloxacin
was 42% in our study, which was lower than that in Scot-
land (87.5%, 2007) and higher than that in Sweden (15.0%,
2009). The resistance rate to clindamycin was 60% in our
study, which was lower than in Canada (90.9%, 2009)
and higher than that in Hungary (27.5%, 2009) [27]. 
The MICs of ampicillin, piperacillin, piperacillin-
tazobactam, cefoxitin, cefotetan, imipenem, metronida-
zole, and vancomycin were not significantly different
according to the toxin status. However, the MIC50 values
of clindamycin and moxifloxacin in A-B+ strains were sig-
nificantly higher than those of A+B+ strains: 128 and 16
in A-B+ versus 4 and 1 in A+B+, respectively (data not
shown). It was reported that higher MICs of antimicro-
bial agents for predominant C. difficile strains may have
played a role in their persistence and dissemination in
hospitals [28, 29]. Therefore, the increased prevalence of
A-B+ strains in this study may reflect their higher MICs
and the selective advantage it allows. This is the first
nationwide study on the toxigenic status, including
molecular genotyping and antimicrobial susceptibility
pattern, of C. difficile isolates in South Korea. The
prevalence of A-B+ and CDT+ strains was 25.7% and 7.1%,
respectively. Surveys of all A-B+ strains showed that the
most common ribotype was ribotype 017. We isolated 1
ribotype 027 strain, which is regarded as a historic iso-
late, with susceptibility to moxifloxacin. The prevalence
of ribotype 078 was 3.1%, which was higher than that of
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ribotype 027. We did not isolate strains with decreased
susceptibility to MTZ or VAN, since these 2 antimicro-
bial agents can be used without an antimicrobial sus-
ceptibility test.  
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